The Europe rhinoconjunctivitis market is estimated to grow at a healthy CAGR during the forecast period.
The growth of the European rhinoconjunctivitis market is majorly driven by the growing prevalence of ocular allergies in the Europe region. Ocular allergies also known as allergic conjunctivitis, is a very common eye disease. Additionally, other allergic problems like rhinitis disease have symptoms such as nasal itching, sneezing, rhinorrhoea, and nasal blockage which are major inconveniences. Allergic diseases are among the most common noncommunicable illnesses seen in many populations in this region and this prevalence is expected to negatively impact the quality of life and sleep resulting in less productivity in the workplace. People who are aged between 15-64 years are more prone to suffering from allergic diseases. As a result, populations are preferring to have treatment for allergies, which is driving the growth rate of the European market.
The growing pollution levels across the European region are further fuelling the growth rate of the European rhinoconjunctivitis market. Outdoor air pollution is a significant problem that impacts the population's health in several ways. Due to the growing number of vehicles and factories, the quality of air is decreasing in recent years, leading to several health issues in the population such as allergies, sneezing, etc. Any type of air pollution may impact the eye or nasal way which may lead to allergies and eye issues.
Increasing adoption of technological advancements for the development and manufacturing of new types of drugs by pharmaceutical companies is contributing to the European rhinoconjunctivitis market growth. An increasing number of clinical trials for the development of drugs like nasal sprays, eye drops, and solid medication also demand market growth. Increasing research and development, increasing drug approvals, and increasing investment by the government are favoring the European market growth.
On the other side, poor awareness among the European population about rhino conjunctivitis is one of the major factors hampering the European market growth. Lack of skilled professionals for the research sector, long-time approvals of allergic drugs, and lack of proper infrastructure are the other factors that hamper the market growth during the forecast period in the European region. The increasing negligence about the importance of eye health also challenges market growth.
This research report on the Europe rhinoconjunctivitis market has been segmented and sub-segmented into the following categories.
By Treatment:
By Country:
Geographically, the European region accounted for a substantial share of the worldwide market during the forecast period owing to increasing awareness about the symptoms of rhinoconjunctivitis disease among the population. The governments of European countries take several initiatives to increase awareness about allergic symptoms and their consequence to the population by conducting several programs orchestrated by healthcare organizations and the major key players. Additionally, the European Forum for Research and Education in Allergy and Airways diseases has taken several steps to ensure minimal care for patients who are suffering from allergies and chronic respiratory conditions.
The UK rhinoconjunctivitis market held the major share of the European market in 2022 and is expected to grow at a healthy CAGR during the forecast period. As per the survey in the United Kingdom, 10-15% of children and 25 percent of adults are suffering from allergic rhinitis. Some people treat this condition as hay fever. Many children face several issues during allergic rhinitis such as low performance in school, less food intake, etc. This allergic disease may be caused due to airborne allergens from grasses, plants, trees, weeds, and outdoor molds which are wind pollinated. Grass pollen is the main reason for allergic rhinitis also known as hay fever. This is mostly seen in school during the annual examination which is mostly taken in the summer month.
German rhinoconjunctivitis is predicted to grow at a notable CAGR during the forecast period owing to the growing number of hospitals and clinics specifically for allergic diseases. Most people in Germany are preferring to have immune therapy for allergic diseases.
KEY MARKET PLAYERS:
Promising Companies dominating the Europe Rhinoconjunctivitis Market Profiled in the Report are Johnson & Johnson Inc., Merck & Co., Inc., GlaxoSmithKline, Sanofi and Adiga Life Sciences Inc.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region